Jarosław Dróżdż
A5043527909- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiac Valve Diseases and Treatments
- Diabetes Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Disease and Adiposity
- Cardiac Arrhythmias and Treatments
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Cardiac tumors and thrombi
- Cardiac electrophysiology and arrhythmias
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Advanced MRI Techniques and Applications
- Cardiomyopathy and Myosin Studies
- Cardiovascular Health and Disease Prevention
- Health Systems, Economic Evaluations, Quality of Life
- Potassium and Related Disorders
- Heart Rate Variability and Autonomic Control
- Venous Thromboembolism Diagnosis and Management
- Blood Pressure and Hypertension Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Metabolism, Diabetes, and Cancer
Medical University of Lodz
2016-2025
Central Clinical Hospital
2021-2023
University of Glasgow
2023
University of Belgrade
2021-2022
Nicolaus Copernicus University
2021
NYU Langone Health
2020
Foundation of Cardiac Surgery Development
2020
Royal Brompton Hospital
2020
San Raffaele University of Rome
2018
Centralny Szpital Kliniczny
2018
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter (SGLT2) reduce the risk a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding effects SGLT2 in established failure and reduced ejection fraction, regardless presence or absence diabetes.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic a left ventricular ejection fraction 40% or less. Whether SGLT2 are effective in higher remains less certain.
The assessment of myocardial viability has been used to identify patients with coronary artery disease and left ventricular dysfunction in whom coronary-artery bypass grafting (CABG) will provide a survival benefit. However, the efficacy this approach is uncertain.In substudy who were enrolled randomized trial medical therapy or without CABG, we single-photon-emission computed tomography (SPECT), dobutamine echocardiography, both assess on basis prespecified thresholds.Among 1212 trial, 601...
Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment patients HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in HFrEF and diabetes.Exploratory analysis a phase 3 randomized trial conducted at 410 sites 20 countries. Patients New York Heart Association classification II to IV less than or equal 40% elevated plasma N-terminal pro B-type natriuretic...
This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve Lives Patients With Preserved Ejection Fraction Heart Failure) trial participants how these compare with those in other contemporary heart failure preserved ejection fraction trials.The was designed evaluate effects sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, (HF) hospitalization, or urgent HF visits patients mildly reduced left ventricular...
Background: Frailty may modify the risk−benefit profile of certain treatments, and frail patients have reduced tolerance to treatments. Objective: To investigate efficacy dapagliflozin according frailty status, using Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin Prevention Adverse Outcomes Heart Failure). Design: Post hoc analysis a phase 3 randomized clinical trial. (ClinicalTrials.gov: NCT03036124) Setting: 410 sites 20 countries. Patients: Patients with symptomatic heart...
Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be likely receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according status heart failure mildly reduced or preserved ejection fraction randomized DELIVER (Dapagliflozin Evaluation Improve Lives Patients With Preserved Ejection Fraction Heart Failure).
Aims To perform a comprehensive characterization of acute heart failure (AHF) with preserved (HFpEF), versus mildly reduced (HFmrEF) ejection fraction (HFrEF). Methods and results Of 5951 participants in the ESC HF Long‐Term Registry hospitalized for AHF (acute coronary syndromes excluded), 29% had HFpEF, 18% HFmrEF, 53% HFrEF. Hospitalization reasons were most commonly atrial fibrillation (more HFmrEF HFpEF), followed by ischaemia (HFmrEF), infection (HFmrEF worsening renal function...
Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for AFFIRM-AHF population.The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed 1058 (535 523) patients in FCM groups, respectively, administered prior to randomization at Weeks 2, 4, 6, 12, 24, 36, 52. The KCCQ-12 overall summary score (OSS) mean ± standard...
Abstract With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management this growing population, categorized as improved EF (HFimpEF), which has a high event rate and been excluded from virtually all prior outcomes trials. In prespecified analysis DELIVER trial ( NCT03619213 ), total 6,263 participants symptomatic left...
Background To evaluate the risks factors of atrial fibrillation (AF) following coronary artery bypass grafting (CABG). Methods and Results Twelve hundred patients subjected to CABG were included. Postoperative AF developed in 278 (23.2%). Statistical analysis identified 5 independent predictors AF: advanced age, history supraventricular arrhythmias, preoperative heart failure, operation with standard technique repeated revascularization. Conclusions caused a significant increase mortality...
In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced risk mortality heart failure (HF) hospitalization. We examined frequency significance episodes outpatient HF worsening, requiring augmentation oral therapy, effects dapagliflozin on these additional events.
Personalized management involving heart failure (HF) etiology is crucial for better prognoses HF patients. This study aimed to compare patients with ischemic cardiomyopathy (ICM) and non-ischemic dilated (NIDCM) in terms of baseline characteristics prognosis. We assessed 895 reduced left ventricular ejection fraction participating the Polish part European Society Cardiology (ESC)-HF registries. ICM was present 583 (65%), NIDCM 312 (35%). The were older (